{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:44:23Z","timestamp":1782729863937,"version":"3.54.5"},"reference-count":63,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["15\/57\/143"],"award-info":[{"award-number":["15\/57\/143"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Despite the relative success of immuno-modulatory disease-modifying therapy in relapsing remitting multiple sclerosis, progressive worsening of disability remains a major problem, particularly for those with secondary progressive multiple sclerosis. Various underlying mechanisms are likely to contribute, augmented by comorbidities (such as vascular risk) and ageing. In the phase 2b MS-STAT trial, simvastatin (80\u2005mg) (Sandoz Ltd, Camberley, UK) reduced the mean annualised whole brain atrophy rate by 43% compared to placebo in patients with secondary progressive multiple sclerosis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2005=\u20050.003). We now report the phase 3, MS-STAT2 trial, with confirmed progression of disability as the primary outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre, phase 3, randomised, double-blind, placebo-controlled clinical trial was conducted at 31 UK neuroscience centres and district general hospitals. Secondary progressive multiple sclerosis participants aged 18\u201365 years were randomised 1\u2005:\u20051 to oral simvastatin (80\u2005mg), or matched placebo, based on a minimisation algorithm that incorporated the following factors: sex (male\/female); age (&lt; or \u2265\u200545 years); Expanded Disability Status Scale baseline score (\u2264\u20055.5 or \u2265\u20056); whether participants were taking newly licensed (2017 onward) disease-modifying treatments for secondary progressive multiple sclerosis; and trial site. An independent and secure online randomisation service was used. All participants, site investigators and the trial co-ordinating team were blinded to treatment allocation. The Expanded Disability Status Scale was measured every 6 months and was compared to baseline scores, with remote data collection used when enforced by the COVID-19 pandemic. The primary outcome was time to Expanded Disability Status Scale-confirmed disability progression. Progression of disability was defined as an increase of at least one point on the Expanded Disability Status Scale if the baseline score was &lt;\u20056, or an increase of 0.5 point if the baseline score was \u2265\u20056. The initial disability progression event was finalised as confirmed if the increase in Expanded Disability Status Scale score persisted at the next assessments \u2265\u20056 months later. Follow-up was for 36 months, or 54 months, for those without confirmed disability progression at 36 months who agreed to enter an optional blinded extension. An intention-to-treat analysis was carried out.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      The study was conducted between 10 May 2018 and 26 July 2024. There were 964 participants randomised, with 482 in the placebo group and 482 in the simvastatin group. 173 (35.9%) participants in the placebo group and 192 (39.8%) participants in the simvastatin group experienced Expanded Disability Status Scale-confirmed disability progression (adjusted hazard ratio =\u20051.13, 95% confidence interval 0.91 to 1.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2005=\u20050.263). No material differences in the secondary outcomes were observed. No major safety issues were seen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>The MS-STAT2 trial did not demonstrate a treatment effect of simvastatin in slowing disability progression in participants with secondary progressive multiple sclerosis. Despite the favourable outcomes of the previous phase 2b trial, simvastatin use in secondary progressive multiple sclerosis should be confined to existing vascular indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 15\/57\/143.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/gjjc5820","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T14:25:04Z","timestamp":1755699904000},"page":"1-41","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8197-0177","authenticated-orcid":true,"given":"Thomas","family":"Williams","sequence":"first","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-5269","authenticated-orcid":true,"given":"James","family":"Blackstone","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9834-4498","authenticated-orcid":true,"given":"Nevin","family":"John","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0634-8350","authenticated-orcid":true,"given":"Marie","family":"Braisher","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-1435","authenticated-orcid":true,"given":"Floriana","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5541-5818","authenticated-orcid":true,"given":"Alessa","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-2803","authenticated-orcid":true,"given":"Alberto","family":"Calvi","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-8668","authenticated-orcid":true,"given":"Anisha","family":"Doshi","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-7823","authenticated-orcid":true,"given":"Sean Apap","family":"Mangion","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5199-7566","authenticated-orcid":true,"given":"Charles","family":"Wade","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-7049","authenticated-orcid":true,"given":"Ekaterina","family":"Bordea","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7913-5105","authenticated-orcid":true,"given":"Rachel","family":"Merry","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3998-2542","authenticated-orcid":true,"given":"Gil","family":"Barton","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-7930","authenticated-orcid":true,"given":"Dawn","family":"Lyle","sequence":"additional","affiliation":[{"name":"Anne Rowling Regenerative Neurology Clinic, NHS Lothian, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-6138","authenticated-orcid":true,"given":"Elisabeth","family":"Jarman","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-4185","authenticated-orcid":true,"given":"Don","family":"Mahad","sequence":"additional","affiliation":[{"name":"Anne Rowling Regenerative Neurology Clinic, NHS Lothian, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shehu","sequence":"additional","affiliation":[{"name":"University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-3615","authenticated-orcid":true,"given":"Tarunya","family":"Arun","sequence":"additional","affiliation":[{"name":"University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5716-8485","authenticated-orcid":true,"given":"Gavin","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5829-808X","authenticated-orcid":true,"given":"Ruth","family":"Geraldes","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Craner","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5496-4858","authenticated-orcid":true,"given":"Charles","family":"Hillier","sequence":"additional","affiliation":[{"name":"University Hospitals Dorset NHS Foundation Trust, Poole, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0440-5720","authenticated-orcid":true,"given":"Jeban","family":"Ganesalingam","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5059-7816","authenticated-orcid":true,"given":"Leonora","family":"Fisniku","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-7920","authenticated-orcid":true,"given":"Jeremy","family":"Hobart","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth NHS Trust, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3270-7614","authenticated-orcid":true,"given":"Cord","family":"Spilker","sequence":"additional","affiliation":[{"name":"St Luke\u2019s Hospital, Bradford Teaching Hospitals Foundation Trust, Bradford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-4909","authenticated-orcid":true,"given":"Neil P","family":"Robertson","sequence":"additional","affiliation":[{"name":"University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5405-2445","authenticated-orcid":true,"given":"Seema","family":"Kalra","sequence":"additional","affiliation":[{"name":"University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-9472","authenticated-orcid":true,"given":"Stefano","family":"Pluchino","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences and NIHR Biomedical Research Centre, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9130-9932","authenticated-orcid":true,"given":"Sreedharan","family":"Harikrishnan","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Foundation Trust, Canterbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8426-194X","authenticated-orcid":true,"given":"Miriam","family":"Mattoscio","sequence":"additional","affiliation":[{"name":"Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-9726","authenticated-orcid":true,"given":"Timothy","family":"Harrower","sequence":"additional","affiliation":[{"name":"NIHR Exeter Biomedical Research Centre, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-7720","authenticated-orcid":true,"given":"Carolyn","family":"Young","sequence":"additional","affiliation":[{"name":"Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1697-0365","authenticated-orcid":true,"given":"Martin","family":"Lee","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-5582","authenticated-orcid":true,"given":"Suresh Kumar","family":"Chhetri","sequence":"additional","affiliation":[{"name":"Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-0889","authenticated-orcid":true,"given":"Fayyaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7262-4248","authenticated-orcid":true,"given":"David","family":"Rog","sequence":"additional","affiliation":[{"name":"Northern Care Alliance NHS Foundation Trust, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3972-0780","authenticated-orcid":true,"given":"Eli","family":"Silber","sequence":"additional","affiliation":[{"name":"Lewisham and Greenwich NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3448-3182","authenticated-orcid":true,"given":"Paul","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2393-8977","authenticated-orcid":true,"given":"Martin","family":"Duddy","sequence":"additional","affiliation":[{"name":"Royal Victoria Infirmary, Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7183-4002","authenticated-orcid":true,"given":"Agne","family":"Straukiene","sequence":"additional","affiliation":[{"name":"Torbay & South Devon NHS Foundation Trust, Torbay, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0414-1225","authenticated-orcid":true,"given":"Richard","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-4426","authenticated-orcid":true,"given":"Claire","family":"Rice","sequence":"additional","affiliation":[{"name":"North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tebbs","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-5899","authenticated-orcid":true,"given":"Annie","family":"Hawton","sequence":"additional","affiliation":[{"name":"University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-8934","authenticated-orcid":true,"given":"Rachael","family":"Hunter","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Population Health, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":true,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[{"name":"Blizard Institute, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1367","authenticated-orcid":true,"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Beveridge","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Society UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Nixon","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Society UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-8496","authenticated-orcid":true,"given":"Alan J","family":"Thompson","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4496-2984","authenticated-orcid":true,"given":"John","family":"Greenwood","sequence":"additional","affiliation":[{"name":"Institute of Ophthalmology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-0200","authenticated-orcid":true,"given":"Owen","family":"Pearson","sequence":"additional","affiliation":[{"name":"Morriston Hospital, Swansea Bay University Health Board, Swansea, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-0672","authenticated-orcid":true,"given":"Nikos","family":"Evangelou","sequence":"additional","affiliation":[{"name":"Queens Medical Centre, Nottingham University Hospital NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3594-7534","authenticated-orcid":true,"given":"Basil","family":"Sharrack","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-5102","authenticated-orcid":true,"given":"Ian","family":"Galea","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-440X","authenticated-orcid":true,"given":"Sue","family":"Pavitt","sequence":"additional","affiliation":[{"name":"University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-1593","authenticated-orcid":true,"given":"Siddharthan","family":"Chandran","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research, Biomedical Research Centre, University College London Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-5046","authenticated-orcid":true,"given":"Helen L","family":"Ford","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6023-0391","authenticated-orcid":true,"given":"Jennifer M","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7286-6901","authenticated-orcid":true,"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2026,6]]},"reference":[{"key":"key2026062915035200_ref2-bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"key2026062915035200_ref3-bib3","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"key2026062915035200_ref4-bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/pn-2024-004228","article-title":"Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance","volume":"25","author":"Rashid","year":"2024","journal-title":"Pract Neurol"},{"key":"key2026062915035200_ref5-bib5","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"key2026062915035200_ref6-bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12883-022-02820-0","article-title":"Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil","volume":"22","author":"Vasanthaprasad","year":"2022","journal-title":"BMC Neurol"},{"key":"key2026062915035200_ref7-bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","article-title":"Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges","volume":"23","author":"Chataway","year":"2024","journal-title":"Lancet Neurol"},{"key":"key2026062915035200_ref8-bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1474-4422(14)70264-9","article-title":"Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives","volume":"14","author":"Ontaneda","year":"2015","journal-title":"Lancet Neurol"},{"key":"key2026062915035200_ref9-bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2022","journal-title":"Lancet Neurol"},{"key":"key2026062915035200_ref10-bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","article-title":"Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis","volume":"18","author":"Yong","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"key2026062915035200_ref11-bib11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"key2026062915035200_ref12-bib12","doi-asserted-by":"crossref","first-page":"1591605","DOI":"10.1177\/13524585221083194","article-title":"Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: analysis of EXPAND core and extension data up to >5 years","volume":"28","author":"Cree","year":"2022","journal-title":"Mult Scler"},{"key":"key2026062915035200_ref13-bib13","first-page":"1","article-title":"Authorisation details: Mayzent (siponimod)","volume":"44","author":"European Medicines Agency (EMA)","year":"2021"},{"key":"key2026062915035200_ref14-bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"},{"key":"key2026062915035200_ref15-bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nri1839","article-title":"Statin therapy and autoimmune disease: from protein prenylation to immunomodulation","volume":"6","author":"Greenwood","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"key2026062915035200_ref16-bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.it.2006.12.003","article-title":"Statins and the vascular endothelial inflammatory response","volume":"28","author":"Greenwood","year":"2007","journal-title":"Trends Immunol"},{"key":"key2026062915035200_ref17-bib17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1096\/fj.02-1014fje","article-title":"Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis","volume":"17","author":"Greenwood","year":"2003","journal-title":"FASEB J"},{"key":"key2026062915035200_ref18-bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jneuroim.2006.06.006","article-title":"Statins in the treatment of central nervous system autoimmune disease","volume":"178","author":"Weber","year":"2006","journal-title":"J Neuroimmunol"},{"key":"key2026062915035200_ref19-bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pneurobio.2009.02.002","article-title":"Statins: mechanisms of neuroprotection","volume":"88","author":"van der Most","year":"2009","journal-title":"Prog Neurobiol"},{"key":"key2026062915035200_ref20-bib20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1474-4422(11)70144-2","article-title":"Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial","volume":"10","author":"Sorensen","year":"2011","journal-title":"Lancet Neurol"},{"key":"key2026062915035200_ref21-bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1212\/WNL.0b013e31824f7fdd","article-title":"Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study","volume":"78","author":"Waubant","year":"2012","journal-title":"Neurology"},{"key":"key2026062915035200_ref22-bib22","first-page":"412","article-title":"Statins for multiple sclerosis","volume":"364","author":"Wang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026062915035200_ref23-bib23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.2146\/ajhp110675","article-title":"Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis","volume":"69","author":"Bhardwaj","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"key2026062915035200_ref24-bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458511415452","article-title":"Simvastatin improves final visual outcome in acute optic neuritis: a randomized study","volume":"18","author":"Tsakiri","year":"2012","journal-title":"Mult Scler"},{"key":"key2026062915035200_ref25-bib25","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"key2026062915035200_ref26-bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(17)30113-8","article-title":"Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial","volume":"16","author":"Chan","year":"2017","journal-title":"Lancet Neurol"},{"key":"key2026062915035200_ref27-bib27","doi-asserted-by":"crossref","first-page":"e1130","DOI":"10.1212\/NXI.0000000000001130","article-title":"Assessing neurofilaments as biomarkers of neuroprotection in progressive multiple sclerosis","volume":"9","author":"Williams","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"key2026062915035200_ref28-bib28","doi-asserted-by":"crossref","first-page":"P7","DOI":"10.1212\/WNL.84.14_supplement.P7.259","article-title":"Smaller baseline brain volume and higher atrophy rate over two years is associated with poorer clinical outcomes: post hoc analysis of the MS-STAT trial in Secondary Progressive MS (P7. 259)","volume":"84","author":"Chataway","year":"2015","journal-title":"Neurology"},{"key":"key2026062915035200_ref29-bib29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaneurol.2020.0664","article-title":"Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England","volume":"77","author":"Palladino","year":"2020","journal-title":"JAMA Neurol"},{"key":"key2026062915035200_ref30-bib30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1352458514564485","article-title":"A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"key":"key2026062915035200_ref31-bib31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"key":"key2026062915035200_ref32-bib32","doi-asserted-by":"crossref","first-page":"e70058","DOI":"10.1111\/ene.70058","article-title":"Smoking and obesity interact to adversely affect disease progression and cognitive performance in multiple sclerosis","volume":"32","author":"Eva","year":"2025","journal-title":"Eur J Neurol"},{"key":"key2026062915035200_ref33-bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp-2022-330848","article-title":"Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression","volume":"94","author":"Wu","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key2026062915035200_ref34-bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1352458520984746","article-title":"Cardiometabolic comorbidity is associated with longitudinal total brain and gray matter compartment atrophy in a large multiple sclerosis cohort","volume":"27","author":"Fitzgerald","year":"2021","journal-title":"Mult Scler J"},{"key":"key2026062915035200_ref35-bib35","doi-asserted-by":"crossref","first-page":"e1729","DOI":"10.1212\/WNL.0000000000207777","article-title":"Exploring the role of plasma lipids and statin interventions on multiple sclerosis risk and severity: a Mendelian randomization study","volume":"101","author":"Almramhi","year":"2023","journal-title":"Neurology"},{"key":"key2026062915035200_ref36-bib36","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.1073\/pnas.1818978116","article-title":"Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis","volume":"116","author":"Eshaghi","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"key2026062915035200_ref37-bib37","doi-asserted-by":"crossref","first-page":"e086414","DOI":"10.1136\/bmjopen-2024-086414","article-title":"Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK","volume":"14","author":"Blackstone","year":"2024","journal-title":"BMJ Open"},{"key":"key2026062915035200_ref38-bib38","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0140-6736(25)01039-6","article-title":"Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"406","author":"Chataway","year":"2025","journal-title":"Lancet"},{"key":"key2026062915035200_ref39-bib39","volume-title":"2020\/21 National Cost Collection Data 2022","author":"NHS England"},{"key":"key2026062915035200_ref40-bib40","volume-title":"University of Kent 2021","author":"Jones"},{"key":"key2026062915035200_ref41-bib41","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2024"},{"key":"key2026062915035200_ref42-bib42","volume-title":"Earnings and Hours Worked, All Employees (2021 Edition) 2022","author":"White","year":"2022"},{"key":"key2026062915035200_ref43-bib43","volume-title":"ResearchSquare","author":"Bordea","year":"2025"},{"key":"key2026062915035200_ref44-bib44","doi-asserted-by":"crossref","first-page":"e70286","DOI":"10.1111\/ene.70286","article-title":"Executive dysfunction and disability in SPMS: predictive value of the frontal assessment battery in the UCLH MS-STAT2 cohort","volume":"32","author":"Wade","year":"2025","journal-title":"Eur J Neurol"},{"key":"key2026062915035200_ref45-bib45","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s10072-023-06838-1","article-title":"Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study","volume":"44","author":"Papathanasiou","year":"2023","journal-title":"Neurol Sci"},{"key":"key2026062915035200_ref46-bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"key":"key2026062915035200_ref47-bib47","article-title":"Efficacy and safety of tolebrutinib versus placebo in non-relapsing secondary progressive multiple sclerosis: results from the phase 3 HERCULES Trial","volume":"92","author":"Fox","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"key2026062915035200_ref48-bib48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","article-title":"Comorbidity in multiple sclerosis: implications for patient care","volume":"13","author":"Marrie","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"key2026062915035200_ref49-bib49","doi-asserted-by":"crossref","first-page":"e209135","DOI":"10.1212\/WNL.0000000000209135","article-title":"Investigating the prevalence of comorbidity in multiple sclerosis clinical trial populations","volume":"102","author":"Salter","year":"2024","journal-title":"Neurology"},{"key":"key2026062915035200_ref51-bib51","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/brain\/awaa231","article-title":"Delay from treatment start to full effect of immunotherapies for multiple sclerosis","volume":"143","author":"Roos","year":"2020","journal-title":"Brain"},{"key":"key2026062915035200_ref52-bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.msard.2017.01.007","article-title":"Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses","volume":"12","author":"Giovannoni","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"key2026062915035200_ref53-bib53","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis","volume":"398","author":"Joseph","year":"2021","journal-title":"Lancet"},{"key":"key2026062915035200_ref54-bib54","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/1352458517708687","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom","volume":"23","author":"Thompson","year":"2017","journal-title":"Mult Scler"},{"key":"key2026062915035200_ref55-bib55","volume-title":"Comparative CNS Pharmacology of Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating MS (S46.007)","author":"Turner","year":"2023"},{"key":"key2026062915035200_ref57-bib57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1191\/1352458503ms884oa","article-title":"Can the Expanded Disability Status Scale be assessed by telephone?","volume":"9","author":"Lechner-Scott","year":"2003","journal-title":"Mult Scler"},{"key":"key2026062915035200_ref59-bib59","volume-title":"CCMR2 Randomised Controlled Trial","author":"Cambridge Centre for Myelin Repair","year":"2023"},{"key":"key2026062915035200_ref60-bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-017-2378-5","article-title":"What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK","volume":"19","author":"Duley","year":"2018","journal-title":"Trials"},{"key":"key2026062915035200_ref61-bib61","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1186\/s13063-022-06588-z","article-title":"Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials","volume":"23","author":"Williams","year":"2022","journal-title":"Trials"},{"key":"key2026062915035200_ref62-bib62","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000011123","article-title":"Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis","volume":"96","author":"Koch","year":"2021","journal-title":"Neurology"},{"key":"key2026062915035200_ref63-bib63","volume-title":"Highest Level of Qualification","author":"Office for National Statistics"},{"key":"key2026062915035200_ref64-bib64","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.stem.2024.09.014","article-title":"Increased cholesterol synthesis drives neurotoxicity in patient stem cell-derived model of multiple sclerosis","volume":"31","author":"Ionescu","year":"2024","journal-title":"Cell Stem Cell"},{"key":"key2026062915035200_ref65-bib65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41593-020-00757-6","article-title":"Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis","volume":"24","author":"Berghoff","year":"2021","journal-title":"Nat Neurosci"},{"key":"key2026062915035200_ref66-bib66","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.tins.2022.01.001","article-title":"Local cholesterol metabolism orchestrates remyelination","volume":"45","author":"Berghoff","year":"2022","journal-title":"Trends Neurosci"},{"key":"key2026062915035200_ref67-bib67","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1111\/ene.15924","article-title":"Cardiovascular risk factors in secondary progressive multiple sclerosis: a cross\u2010sectional analysis from the MS\u2010STAT2 randomized controlled trial","volume":"30","author":"Williams","year":"2023","journal-title":"Eur J Neurol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2051440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJJC5820\/GJJC5820.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2051440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:46:40Z","timestamp":1782726400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/GJJC5820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":63,"alternative-id":["10.3310\/GJJC5820"],"URL":"https:\/\/doi.org\/10.3310\/gjjc5820","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"03-2017","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"04-2025","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"10-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}